AAM Statement on Signing of USMCA by President | Association for Accessible Medicines

AAM Statement on Signing of USMCA by President

WASHINGTON, DC (November 30, 2018) – AAM is extremely concerned that the USMCA, if left in its current form, will decrease prescription drug competition, inevitably leading to increased drug prices in the United States. This will harm American patients, job creators, workers and taxpayers. Furthermore, several provisions within the agreement are inconsistent with U.S. law and, if left unchanged, could lead to inappropriate changes in U.S. law or cause the nation to be in violation of the agreement on day one of its enactment. We call on members of Congress to improve this agreement before it is approved in order to help achieve the goal of lowering prescription drug prices for Americans by facilitating biosimilar and generic drug competition.

Attribute to: Chip Davis, President and CEO

Learn more and take action to #FixUSMCA at MedsforAmerica.org.

View AAM Letter to USTR 

View Coalition Letter 

 

MEDIA CONTACT:
Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.